VENETOCLAX FOR OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN THE DUTCH REAL-WORLD: USAGE AND OUTCOMES

EHA Library, Benno Diekmann, 4159917

EFFICACY AND SAFETY OF OLUTASIDENIB MONOTHERAPY IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA: A POST HOC ANALYSIS OF A PHASE 2 STUDY

EHA Library, Antonio Curti, 4159918

A NEW GENETIC MODEL PREDICTING OUTCOMES IN UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING AZACTIDINE AND VENETOCLAX THERAPY:A MULTI-CENTER STUDY IN THE REAL WORLD

EHA Library, Lu Yu, 4159919

RNA-SEQ FOR IDENTIFICATION OF TARGETABLE ALTERATIONS IN AML

EHA Library, Georgina El Hajjar, 4159920

PROGNOSTIC IMPACT OF BCOR/BCORL1 MUTATIONS IN ND-AML PATIENTS TREATED WITH VEN-HMA

EHA Library, Guillaume BERTON, 4159921

VARIANT T(8;21) TRANSLOCATIONS IN AML: DISTINCT CLINICAL OUTCOMES AND MUTATION PROFILES COMPARED TO CLASSIC T(8;21)

EHA Library, Bingbing Han, 4159922

EFFECT OF MUTATION TYPE AND CO-MUTATIONS ON RESPONSE TO OLUTASIDENIB IN PATIENTS WITH RELAPSED/REFRACTORY MUTATED IDH1 AML

EHA Library, Stéphane De Botton, 4159923

CLINICAL AND MOLECULAR CHARACTERISTICS OF AML WITH NUP98::HOXA9 FUSION: A COMPREHENSIVE ANALYSIS OF 116 CASES

EHA Library, Cui Wang, 4159924

MEASURABLE RESIDUAL DISEASE TEST RESULTS OVER-RIDE IMPACT OF FLT3-ITD ON RELAPSE RISK IN ACUTE MYELOID LEUKAEMIA

EHA Library, Nan Yan, 4159925

OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN RUSSIA AND BELARUS TREATED ON THE APL 2003/2008 PROTO?OLS

EHA Library, Olga Aleinikova, 4159926

VENETOCLAX AND AZACYTIDINE IN CHILDHOOD MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA: THE AIEOP EXPERIENCE

EHA Library, Francesco Baccelli, 4159927

MUTATIONAL LANDSCAPE AND PROGNOSTIC IMPLICATIONS IN KMT2A-R ACUTE MYELOID LEUKEMIA

EHA Library, Jiajia Pan, 4159928

COMPARISON OF EARLY DEATH PREDICTIVE MODELS IN NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Yinjun Lou, 4159929

INNOVATIVE PERSONALIZED TARGET-SELECTED CAR-T CELLS: A PHASE I CLINICAL TRIAL FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Hai Yi, 4159930

VENETOCLAX IN COMBINATION WITH CYTARABINE AND ACTINOMYCIN D (ACTIVE) FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Andrius Žučenka, 4159931

THREE PATTERNS OF MOLECULAR MINIMAL RESIDUAL DISEASE KINETICS IN VENETOCLAX + AZACITIDINE (V+A) TREATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS

EHA Library, Jiří Mayer, 4159932

LOCAL PAIRWISE METHYLATION DISCORDANCE AS A PREDICTIVE BIOMARKER IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING DECITABINE TREATMENT

EHA Library, Dong Hyun Kim, 4159933

THE EFFECT OF SOCIOECONOMIC DEPRIVATION ON RECEIPT OF INTENSIVE CHEMOTHERAPY AND ENROLMENT IN CLINICAL TRIALS AMONG PATIENTS WITH ACUTE MYELOID LEUKAEMIA IN ENGLAND

EHA Library, Koki Shimizu, 4159934

BIOLOGICAL ACTIVITY AND SAFETY OF GILTERITINIB IN SEQUENTIAL COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH R/R FLT3-ITD AML: INTERIM RESULTS FROM A MULTI-CENTER OPEN-LABEL PHASE 1/2 TRIAL

EHA Library, Philip Connor, 4159935

AML WITH PRDMS REARRANGEMENT: UNIFYING PRDM16 AND MECOM REARRANGEMENTS AS A SINGLE ENTITY BASED ON CLINICAL SIMILARITIES

EHA Library, Bingbing Han, 4159936

OLUTASIDENIB AS MAINTENANCE THERAPY AFTER TREATMENT RESPONSE IN MUTATED IDH1 ACUTE MYELOID LEUKEMIA

EHA Library, Andrew Wei, 4159937

THE EFFICIENCY AND SAFETY OF LOW-DOSE VENETOCLAX AS A PROPHYLAXIS FOR DIFFERENTIATION SYNDROME IN THE INDUCTION REGIMEN OF ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Yin Liu, 4159938

THE PROGNOSTIC VALUE OF THE PARTNER GENE NATURE AND BREAKPOINT LOCALIZATION IN PEDIATRIC KMT2A-POSITIVE AML.

EHA Library, Svetlana Lebedeva, 4159939

REAL-WORLD EVIDENCE FOR PERIPHERAL BLOOD NPM1 MEASURABLE RESIDUAL DISEASE SURVEILLANCE IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA POST FIRST MORPHOLOGICAL REMISSION (CR1).

EHA Library, Siddarth Nayar, 4159940

MRD EVALUATION AFTER THE 1ST INDUCTION COURSE IS AN OPTIMAL TIME POINT FOR DECISION MAKING REGARDING ALLO-HCST IMPLEMENTATION FOR DE NOVO NON-MRC AML PATIENTS

EHA Library, Elena Parovichnikova, 4159941

VENETOCLAX BOOSTING IN ACUTE MYELOID LEUKEMIA (AML): PRELIMINARY PHARMACOKINETIC RESULTS FROM THE HOVON 171 TRIAL

EHA Library, Niels Westra, 4159942

MUTATED RAS IN CHILDHOOD ACUTE MYELOID LEUKEMIA:MUTATED KRAS IS AN INDEPENDENT MARKER OF ADVERSE RISK

EHA Library, Wenyi Wang, 4159943

AML WITH KMT2A PARTIAL TANDEM DUPLICATION (KMT2A-PTD) HARBOR MYELODYSPLASIA-ASSOCIATED MUTATIONS AND MDS-ASSOCIATED IMMUNOPHENOTYPIC ALTERATIONS

EHA Library, Swapnali Joshi, 4159944

PROGNOSTIC ANALYSIS OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH LOW-DOSE ARSENIC TRIOXIDE DURING INDUCTION THERAPY AND INVESTIGATION OF FACTORS INFLUENCING LEUKOCYTOSIS AND DIFFERENTIATION SYNDROME: A REAL-WORLD RETROSPECTIVE STUDY

EHA Library, Fei Xu, 4159945

FLT3-ITD MUTATION ANALYSIS WITH DIFFERENT METHODS IN ACUTE MYELOID LEUKEMIA

EHA Library, Yingchang Mi, 4159946

NUTRITIONAL MONITORING VIA BIOELECTRICAL IMPEDANCE ANALYSIS IN PATIENTS INTENSIVELY TREATED FOR ACUTE MYELOID LEUKEMIA.

EHA Library, Corrado Zuanelli Brambilla, 4159947

CD36: A SURFACE ANTIGEN MOLECULE SIGNIFICANTLY ASSOCIATED WITH POOR PROGNOSIS IN AML

EHA Library, Qing Ma, 4159948

CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) EQUAL OR OVER 60 YEARS IN CHILE. A STUDY FROM GRELAM-CHILE WITHIN AML-PETHEMA EPIDEMIOLOGIC REGISTRY.

EHA Library, Monica Alejandra Romero Riquelme, 4159949

ANALYSIS THE CONCENTRATIONS OF VENETOCLAX AND THE IMPACT OF TRIAZOLE ANTIFUNGALS IN PAIRED SAMPLES OF CSF AND PLASMA AT FIXED TIME POINT IN ACUTE LEUKEMIA PATIENTS

EHA Library, Zhenjiang Li, 4159950

NOT ALL FLT3-MUTATED ACUTE MYELOID LEUKEMIAS ARE OF INTERMEDIATE RISK IN THE ERA OF FLT3 INHIBITORS

EHA Library, Adolfo De La Fuente, 4159951

MANAGEMENT AND OUTCOME OF AML PATIENTS WITH HYPERLEUKOCYTOSIS: A SINGLE-CENTER EXPERIENCE

EHA Library, Julian List, 4159952

FLAG-IDA-VEN FOR FIT OLDER HIGH RISK PATIENTS WITH AML

EHA Library, Avraham Frisch, 4159953

CHARACTERISTICS OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA NOT RECEIVING TREATMENT

EHA Library, Aref Al-Kali, 4159954

RIVER-52: A MULTICENTER, OPEN-LABEL CLINICAL TRIAL OF RVU120 IN PATIENTS WITH RELAPSED OR REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA

EHA Library, Pau Montesinos, 4159955

REAL-WORLD PATIENT MANAGEMENT PRACTICES IN RESPONDERS TO VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Ofir Wolach, 4159956

AZACYTIDINE AND VENETOCLAX IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: A SINGLE-CENTRE EXPERIENCE INCORPORATING THE UPDATED RISK CLASSIFICATION FOR LOW-INTENSITY REGIMENS

EHA Library, Maksim Granatkin, 4159957

UNVEILING GERMLINE VARIANTS IN ACUTE MYELOID LEUKEMIA: INSIGHTS FROM A SINGLE-INSTITUTION ANALYSIS

EHA Library, Anna Krzeczowska, 4159958

IMPACT OF COMPLETE HEMATOLOGIC RESPONSE ON SURVIVAL IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH NON-INTENSIVE REGIMENS

EHA Library, Giacomo Aquilino, 4159959

CLINICAL CHARACTERISTICS AND OUTCOMES OF KIT-MUTATED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY OF 67 PATIENTS

EHA Library, Qingli Ji, 4159960

MOLECULAR FEATURES ASSOCIATED WITH CNS DISEASE IN ACUTE MYELOID LEUKEMIA

EHA Library, Nicole Twardowski, 4159961

SELINEXOR-BASED CHEMOTHERAPY-FREE OR LOW-DOSE CHEMOTHERAPY REGIMENS FOR ACUTE MYELOID LEUKEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROMES: EFFICACY AND SAFETY

EHA Library, Xiwen Tong, 4159962

A META-ANALYSIS ON GILTERITINIB USING REAL-WORLD AND RANDOMIZED TRIAL DATA IN PATIENTS WITH FLT3-MUTATED REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA.

EHA Library, matteo molica, 4159963

REL OVEREXPRESSION DRIVES RESISTANCE TO BTK INHIBITORS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH 2P GAIN

EHA Library, Léa Dehgane, 4159964

BTK-A428D IS A CROSS-RESISTANT MUTATION TO BOTH BTK INHIBITORS AND DEGRADERS

EHA Library, Haitao Wang, 4159965

EBF1 EXPRESSION DEFINES A SUBGROUP OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DIFFERENTIAL BIOLOGICAL FEATURES

EHA Library, Víctor Jiménez-Martínez, 4159966

BIOLOGICAL FEATURES OF B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

EHA Library, Helen Parry, 4159967

THE SECOND GENERATION BTK INHIBITOR ZANUBRUTINIB (ZANU) DEMONSTRATES ROBUST EFFICACY IN BOTH TP53 WILDTYPE AND MUTATED B CANCER CELLS IN PRECLINICAL STUDIES

EHA Library, Haitao Wang, 4159968

THE INFLUENCE OF A WHOLE FOOD PLANT BASED DIET ON CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION

EHA Library, Lea Kurzen, 4159969

A NOVEL EX VIVO 3D LYMPH NODE ENVIRONMENT MORE ACCURATELY REPRODUCE IN VIVO RESPONSES TO IBRUTINIB AND VENETOCLAX IN CHRONIC LYMHOCYTIC LEUKEMIA

EHA Library, Daniela Belloni, 4159970

EVIDENCE FOR A PRE-SWITCHED POPULATION AND UNMUTATED IMMUNOGLOBULIN RECEPTORS IN IGG-EXPRESSING CLL STEREOTYPED SUBSET #4

EHA Library, Anastasia Iatrou, 4159971

HEMATOPOIETIC PROGENITOR KINASE-1 (HPK-1) INHIBITION IMPROVES THE IN VITRO EFFICACY OF BISPECIFIC ANTIBODIES IN CLL

EHA Library, Yair Herishanu, 4159972

T CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS SHOW SIGNS OF ACCELERATED SENESCENCE

EHA Library, Elena Camerini, 4159973

MICRORNA-203A IS ENRICHED IN STROMAL-CELL DERIVED EXTRACELLULAR VESICLES OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AND ASSOCIATED WITH TUMOR BURDEN

EHA Library, David Van Morckhoven, 4159974

DISSECTING MECHANISMS OF MECHANORESPONCE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Marta Sampietro, 4159975

DEVELOPMENT OF A CHARTER FOR IMPROVING CARE FOR PEOPLE LIVING WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): SHARED DECISION-MAKING AS A KEY PRINCIPLE TO DRIVE PERSON-CENTERED CARE

EHA Library, Yasmine Hassan, 4159976

PHASE 1/2 STUDIES OF DZD8586 IN CLL/SLL PATIENTS AFTER COVALENT OR NON-COVALENT BTK INHIBITORS AND BTK DEGRADERS

EHA Library, Jianyong Li, 4159977

BEXOBRUTIDEG (NX-5948), A NOVEL BRUTON'S TYROSINE KINASE (BTK) DEGRADER, DEMONSTRATES RAPID AND DURABLE CLINICAL RESPONSES IN RELAPSED/REFRACTORY CLL: UPDATED FINDINGS FROM AN ONGOING PHASE 1A STUDY

EHA Library, Zulfa Omer, 4159978

MEASURABLE RESIDUAL DISEASE KINETICS WITH FIXED-DURATION ACALABRUTINIB-VENETOCLAX COMBINATIONS IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: DATA FROM THE PHASE 3 AMPLIFY TRIAL

EHA Library, Paolo Ghia, 4159979

PRELIMINARY RESULTS FROM A PHASE 1B STUDY OF NON-COVALENT PAN-MUTANT BTK INHIBITOR DOCIRBRUTINIB (AS-1763) IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES

EHA Library, Nitin Jain, 4159980

PRIMARY ANALYSIS RESULTS OF NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES

EHA Library, Caixia Li, 4159981

PRELIMINARY RESULTS OF THE ONGOING MULTICENTER, PHASE 2 STUDY OF RETREATMENT WITH VENETOCLAX PLUS OBINUTUZUMAB (REVENG) IN PATIENTS WITH RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Matthew Davids, 4159982

INTERPLAY OF COMPLEX KARYOTYPE, IGHV MUTATIONAL STATUS AND TP53/ATM ALTERATIONS AND THEIR IMPACT ON PROGNOSIS IN CLL PATIENTS

EHA Library, Alessandro Baldi, 4159983

PROGNOSTIC IMPACT OF MEASURABLE RESIDUAL DISEASE IN HAIRY CELL LEUKEMIA: A 30 YEARS SINGLE CENTER EXPERIENCE

EHA Library, Beatrice Esposito Vangone, 4159985

DEPLETION OF NORMAL B-CELLS IS ASSOCIATED WITH INCREASED MORTALITY IN EARLY-STAGE CLL

EHA Library, Andy Rawstron, 4159986

SONROTOCLAX MONOTHERAPY FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLL: DATA FROM AN ONGOING PHASE 1/1B STUDY (BGB-11417-101)

EHA Library, Stephen S. Opat, 4159987

THE LANCET GASTROENTEROLOGY & HEPATOLOGY, 7 (2022) 254-261. DOI:10.1016/S2468-1253(21)00297-1 LUCAS GUILLO MD 16.00 ACALABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD EFFICACY AND SAFETY FROM THE FRENCH NATIONAL ACALABRUTINIB OBSERVATIONAL STUDY (NAOS), RESULTS AT 2 YEARS

EHA Library, Anne Quinquenel, 4159988

REAL WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH CLL PREVIOUSLY EXPOSED TO BOTH BTKI AND BCL2I THERAPY, INCLUDING THOSE WITH DOUBLE REFRACTORY DISEASE

EHA Library, Matthew Davids, 4159989

INFECTIONS, SECOND PRIMARY MALIGNANCIES AND AUTOIMMUNE DISEASES IN MONOCLONAL B-CELL LYMPHOCYTOSIS AND EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Arianna Bevilacqua, 4159990

IBROMICS: RESULTS OF A REAL-WORLD STUDY OF PARAMETERS DETERMINING RESPONSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN FIRST LINE WITH SINGLE AGENT IBRUTINIB

EHA Library, José Antonio García Vela, 4159991

REAL-WORLD TREATMENT UTILIZATION PATTERNS, DISCONTINUATION AND HEALTHCARE RESOURCE UTILIZATION OF FIRST-LINE BRUTON TYROSINE KINASE INHIBITORS IN CHRONIC LYMPHOCYTIC LEUKEMIA: AGE-RELATED DISPARITY

EHA Library, Keri Yang, 4159992

TREATMENT PATTERNS AND OUTCOMES IN CLL PATIENTS FOLLOWING CBTKI DISCONTINUATION

EHA Library, Carolyn Owen, 4159993

CROSS-STUDY COMPARISON OF IBRUTINIB IN COMBINATION WITH VENETOCLAX (I+V) VS ACALABRUTINIB IN COMBINATION WITH VENETOCLAX (A+V) IN SUBJECTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Talha Munir, 4159994

RISK OF HYPERTENSION IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) AND TREATED WITH COVALENT BRUTON TYROSINE KINASE INHIBITORS (CBTKI): A REAL-WORLD STUDY

EHA Library, Nicole Lamanna, 4159995

IMMUNOMETABOLIC PROFILING REVEALS TWO TYPES OF METABOLIC DYSFUNCTION IN CLL T CELLS WHICH SHARE MITOCHONDRIAL DEFECTS

EHA Library, Nienke Goedhart, 4159996

NGS STUDY OF PATIENTS WITH A COMBINATION OF CML AND MUTATIONS IN THE JAK2 AND CALR GENES

EHA Library, Daria Kustova, 4159997

ASCIMINIB EXHIBITS A FAVORABLE CARDIOVASCULAR SAFETY PROFILE - A COMPREHENSIVE IN-VITRO MODEL

EHA Library, Ayala Gover Proaktor, 4159998

HIGH MIR-202-5P EXPRESSION AT INITIAL DIAGNOSIS AS A PREDICTIVE BIOMARKER FOR TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA-- A RESULT FROM A NESTED CASE-CONTROL STUDY

EHA Library, Zi-Yuan Nie, 4159999

EXPLORATORY ANALYSIS OF PREVALENT ADDITIONAL GENOMIC ALTERATIONS (AGAS) AT BASELINE (BL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM ASC4FIRST

EHA Library, Timothy Hughes, 4160000

THE STRATEGY OF ASCIMINIB MANAGEMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN TRANSPLANT PRACTICE

EHA Library, Yulia Vlasova, 4160001

INTERIM ANALYSIS (IA) RESULTS FROM ASC2ESCALATE SUPPORT ASCIMINIB (ASC) AS A TREATMENT (TX) OPTION IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) AFTER 1 TYROSINE KINASE INHIBITOR (TKI)

EHA Library, Ehab Atallah, 4160002

NEW PEDIATRIC FORMULATION OF ASCIMINIB IN CHILDREN WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: SECOND INTERIM ANALYSIS OF PHARMACOKINETICS, SAFETY AND GROWTH DATA FROM THE ASC4KIDS STUDY

EHA Library, Markus Metzler, 4160003

ASCIMINIB AFTER ONE PRIOR TYROSINE KINASE INHIBITOR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA - A PHYSICIAN PANEL-BASED CHART REVIEW STUDY IN THE UNITED STATES

EHA Library, David Wei, 4160004

DNMT3A, GATA2 AND SETBP1 VARIANT STATUS IN BONE MARROW MONONUCLEAR CELLS IS PREDICTIVE OF TREATMENT-FREE REMISSION IN CML PATIENTS FROM THE DESTINY TRIAL

EHA Library, Shaun Patterson, 4160005

THE EUTOS LONG-TERM SURVIVAL SCORE PREDICTS FAILURE-FREE SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS IN THE ERA OF SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG-JSH CML STUDY

EHA Library, Fumisato Takagi, 4160006

NEW CHINESE SCORE FOR PREDICTING OUTCOMES TO FIRST-LINE CML THERAPY IS NOT SUPERIOR TO ELTS WHEN TESTED INA EUROPEAN POPULATION WITH AN OLDER MEDIAN AGE: A STUDY FROM THE ITALIAN CML CAMPUS NETWORK

EHA Library, Tiziana Rosso, 4160007

INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEALS THE CLINICAL HETEROGENEITY OF NEWLY-DIAGNOSED ACCELERATED-PHASE CHRONIC MYELOID LEUKEMIA

EHA Library, Mei Bao, 4160009

SUSTAINED IMPAIRMENT OF KIDNEY FUNCTION IN PATIENTS WITH PH+ CML TREATED WITH IMATINIB

EHA Library, Max V. John, 4160010

TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DE NOVO ACCELERATED-PHASE AND/OR TYROSINE KINASE-INHIBITOR FAILURE: A RETROSPECTIVE MULTICENTER STUDY

EHA Library, Mengyao Yuan, 4160011

HLA DIVERSITY IS ASSOCIATED WITH TREATMENT RESPONSE AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Charles Toulemonde, 4160012

BCR::ABL1 KINETICS IN PERIPHERAL BLOOD DURING DOSE DE-ESCALATION PHASE ARE PREDICTIVE OF TFR SUCCESS: A SUB-STUDY OF THE DESTINY CLINICAL TRIAL

EHA Library, Shaun Patterson, 4160013

RECAPITULATION OF PEDIATRIC MDS DISEASE PHENOTYPES USING HIPSCS: THE ROLE OF SETBP1 AND ASXL1 IN THE GATA2 DEFICIENCY

EHA Library, Joan Pera, 4160014

MITOTIC DEFECTS IMPAIRED CD34+ PROLIFERATION IN GATA2 DEFICIENCY

EHA Library, Maria Magallon-Mosella, 4160015

ROLE AND MECHANISM OF ADENOSINERGIC AXIS INVOLVED IN THE FORMATION OF MYELOSUPPRESSIVE IMMUNE MICROENVIRONMENT IN MDS PATIENTS

EHA Library, Zhaoyun Liu, 4160016

HMGB3 AS A CARGO PROTEIN FOR XPO1: IMPLICATIONS FOR MYELODYSPLASTIC SYNDROMES PROGNOSIS AND TREATMENT

EHA Library, Wenli Yang, 4160017

DYSFUNCTIONAL CD4 T CELL SUBSETS CONTRIBUTE TO A DEFICIENT ANTITUMORAL IMMUNE RESPONSE IN LOW-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Ana Aldaz Sagredo, 4160018